Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status - Wikidata - wikimedia - TriplyDB

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

http://www.wikidata.org/entity/Q33620091

about

EGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging.Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma Pharmacological Intervention through Dietary Nutraceuticals in Gastrointestinal Neoplasia.Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity.Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels.Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.Regulation of cysteinyl leukotriene receptor 2 expression--a potential anti-tumor mechanism.Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells The colorectal tumor microenvironment: the next decade.Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.Role of epidermal growth factor receptor in acute and chronic kidney injury.SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression.Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system.Targeted therapeutic agents for colorectal cancer.Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas.MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases.Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins.Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification.Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.Synergistic chemopreventive effects of nobiletin and atorvastatin on colon carcinogenesis.Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors.Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation.Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas.An immunohistochemical study of EGFR expression in colorectal cancer and its correlation with lymph nodes status and tumor grade.Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a comparative study in glioblastoma cells.Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy.Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer.

P2860

Q27325591-A318F7F8-E082-4042-BACB-DC55CF0E6D28 Q28085367-426D8675-CBE3-404C-81A9-49B07F984EE5 Q30252185-B2B44E0F-D7E5-4D25-872B-57806996327D Q31015825-7CA410B0-1D06-42C3-BCCB-B2E55CBDDE18 Q31143290-94415BF3-0B27-4611-850F-C735867CBAF5 Q33274011-7D0B93FB-9BCD-48AD-BE97-69C299D2A1F0 Q33556032-3B487089-9644-4EF7-9708-35EDD30160E0 Q33825878-3205B557-B421-4383-A1D6-CAD37A8DE37C Q33935480-F1D1995E-A7BE-4C4D-A077-EBA20FFEAB08 Q34060487-5B78649A-B18D-4EB0-93E7-B9E7AB046E88 Q34110714-B870E473-4942-4F05-AEFF-73476B8FC7D6 Q34250109-6EECE7A7-C51E-4B5A-9BA6-173851937DC0 Q34597762-15123549-AB88-4F0A-83B9-AA24834A654A Q35206661-7313444C-C26A-4FA7-B750-5C00EB3CD35A Q36071392-30A9929D-4E88-4B36-8AB8-BF12686BB886 Q36200253-6BF16E74-9AA7-40E7-B6B5-EE099998C950 Q36224457-77BCC31D-1282-48EE-9EE9-0B1D12BE5141 Q36245896-0759E39C-EDB8-4A85-BE6A-6A93DFAAC452 Q37059520-5127D998-CD3B-4182-BA22-99765AB80B25 Q37158228-D680515F-7684-42B0-8981-372BD4373314 Q37252262-E9B0C44F-6B7B-4E86-9793-DBA09211B921 Q37930489-49C01863-5CFC-4548-8AAC-9DEDA5968AD1 Q38009277-763351EB-B44E-4044-9B6C-F0F4510AA818 Q38407300-ED9D37F3-406D-42A8-965E-469AA323C4EB Q38491102-3F2FAA6C-C9C5-4D88-BA22-B415FAD71574 Q38716191-552AB608-923B-4A7D-8DC2-C5780042110F Q38751733-CCE83D15-E304-4A7A-B396-C22E0B7C2B63 Q39000135-31D46525-FA6C-4C41-95AC-5A7BCCCAADEF Q39579734-7EBA533F-8329-4092-9D6E-C29BC879CD2C Q42363729-7F54F998-9641-4462-BBB1-1BA1FD4EC177 Q43120733-1E1617D6-CAE4-424E-9B93-412E75717311 Q45030051-AD435238-CBC2-45DE-9159-90CEEA0C634D Q51060657-C1992EFA-00F4-414F-AF72-762C8310F4A6 Q53202983-DABCFC73-B316-487D-BB2A-801DD2C4DC1F Q54378950-36AB12C7-ABEA-4AE4-A96E-4E95FB471D0C

P2860

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

http://www.wikidata.org/entity/Q33620091

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prognostic effect of activated ...... s: comparison with EGFR status

@ast

Prognostic effect of activated ...... s: comparison with EGFR status

@en

type

label

Prognostic effect of activated ...... s: comparison with EGFR status

@ast

Prognostic effect of activated ...... s: comparison with EGFR status

@en

prefLabel

Prognostic effect of activated ...... s: comparison with EGFR status

@ast

Prognostic effect of activated ...... s: comparison with EGFR status

@en

P1433

Q33620091-3D821E52-7551-4B93-B771-10AC236C5DDF

P1476

Q33620091-1A6965FC-A94E-45C7-9899-6C2B1BC368DB

P2093

Q33620091-2419B91B-569A-4F64-A924-6331754A3B2D

Q33620091-24857405-FD41-4C99-8D90-85AAA04A2D6B

Q33620091-24ADC479-7F77-4CF7-AACA-125A5FD813F3

Q33620091-45A08039-5C1B-411D-937E-75904177EBD5

Q33620091-C5F17EB5-6679-4855-85EC-CD6042E61A18

Q33620091-D840BAF6-B471-4C6B-B916-A634D13A6B4E

Q33620091-DCBDC63E-907D-4A9A-90F9-7B9BFDE9B465

P2860

Q33620091-1369343B-D0E1-412D-8D07-856CC8BD8711

Q33620091-2ADFC82D-C9ED-4CEC-B6C7-854CAD38E597

Q33620091-44443112-B4D4-420E-B963-7D776453BEFF

Q33620091-5891E988-93C9-45BC-9F7C-0448E1D54222

Q33620091-6082DFCB-B2BD-474A-B783-D126F6A0740E

Q33620091-669DDAC4-ABD7-4900-9DD1-E76548F751A7

Q33620091-690F502D-988E-4FB1-A541-D4B6E7663DF0

Q33620091-7533BA0A-EBFB-474C-B22E-12F28417E2F5

Q33620091-79619E3B-1202-4BBE-A471-6687E61A23B3

Q33620091-7D87D39B-4C2C-4874-AA68-9ECDA577D971

P2888

Q33620091-3F0D7F7C-5BB4-4420-BBE1-FFAD35C28B7A

P304

Q33620091-02C1F43C-7B9D-48D2-B478-C89A156C45C9

P31

Q33620091-212E50F7-FDCF-43D4-83B2-B5F9E1E91676

P356

Q33620091-9898E9A9-3D3A-4EC6-BE25-61D4F250F092

P407

Q33620091-E6BFFC49-2C38-44BE-B605-4C8C6DF57B1E

P433

Q33620091-08329733-EEE7-48D1-BA88-BC11D7306E3A

P478

Q33620091-6E4AB262-DFF8-4618-879D-717580BE5A39

P50

Q33620091-0F48A75B-97F5-41B9-80F0-3D620AE00914

P577

Q33620091-225CEA75-E93E-43D4-A07B-4950EEF74A90

P5875

Q33620091-4D29DE13-1620-44F2-A31B-83C3C1254E11

P6179

Q33620091-91C97C42-50AA-4D10-A0E3-B20ACA13DB5B

P698

Q33620091-5CE78C40-8B7C-493A-A682-FC4499193FC9

P932

Q33620091-68CBF7FD-75E7-4227-8911-12CBEA20AA98

P356

P1433

British Journal of Cancer

P1476

Prognostic effect of activated ...... s: comparison with EGFR status

@en

P2093

F A Sinicrope

http://www.w3.org/2001/XMLSchema#string

H Windschitl

http://www.w3.org/2001/XMLSchema#string

M J O'Connell

http://www.w3.org/2001/XMLSchema#string

M Le

http://www.w3.org/2001/XMLSchema#string

N R Foster

http://www.w3.org/2001/XMLSchema#string

R L Rego

http://www.w3.org/2001/XMLSchema#string

T C Smyrk

http://www.w3.org/2001/XMLSchema#string

P2860

Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Untangling the ErbB signalling network

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling

In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-src: identification of phosphorylation sites and c-src SH2 domain binding sites

P2888

P304

165-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605473

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Daniel J. Sargent

P577

2009-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40483918

http://www.w3.org/2001/XMLSchema#string

P6179

1009422434

http://www.w3.org/2001/XMLSchema#string

P698

19997103

http://www.w3.org/2001/XMLSchema#string

P932

2813748

http://www.w3.org/2001/XMLSchema#string